Tarsa Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2009-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
7
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
A Study of Oral Recombinant Salmon Calcitonin (rsCT) to Prevent Postmenopausal Osteoporosis
- Conditions
- Osteopenia
- Interventions
- Drug: Oral calcitonin at dinnertimeDrug: Oral placebo at dinnertimeDrug: Oral calcitonin at bedtimeDrug: Oral placebo at bedtime
- First Posted Date
- 2011-02-09
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Tarsa Therapeutics, Inc.
- Target Recruit Count
- 129
- Registration Number
- NCT01292187
- Locations
- 🇺🇸
Diablo Clinical Research, Inc., Walnut Creek, California, United States
🇺🇸Innovative Research of West Florida, Inc., Clearwater, Florida, United States
🇺🇸Bethesda Health Research, Bethesda, Maryland, United States
A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic Women
- Conditions
- Osteoporosis, Postmenopausal
- Interventions
- Drug: Oral Calcitonin TabletsDrug: Intranasal CalcitoninDrug: Placebo tablets and placebo intranasal spray
- First Posted Date
- 2009-08-17
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Tarsa Therapeutics, Inc.
- Target Recruit Count
- 565
- Registration Number
- NCT00959764
- Locations
- 🇺🇸
Rheumatology Associates of N. AL, P.C., Huntsville, Alabama, United States
🇺🇸Northern California Institute for Bone Health, Inc., Oakland, California, United States
🇺🇸Desert Medical Advances, Palm Desert, California, United States
A Study of Oral Calcitonin Given at Night to Healthy Postmenopausal Women
- Conditions
- Phase 1 Pharmacodynamic Study
- Interventions
- First Posted Date
- 2008-12-05
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Tarsa Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT00803686
- Locations
- 🇺🇸
Bio-Kinetic Clinical Applications, Inc., Springfield, Missouri, United States
A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women
- Conditions
- Osteoporosis
- Interventions
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2012-02-01
- Lead Sponsor
- Tarsa Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00620854
- Locations
- 🇺🇸
Bio-Kinetic Clinical Applications, Inc., Springfield, Missouri, United States